Skip to main content
. Author manuscript; available in PMC: 2017 Aug 1.
Published in final edited form as: Expert Rev Mol Diagn. 2016 Jun 23;16(8):811–826. doi: 10.1080/14737159.2016.1194758

Table 2.

Emerging serum biomarkers in ovarian carcinomaa

Marker Sensitivity Specificity References
Osteopontin 77% 90% [22, 24]
Osteopontin & CA125 87% 88% [25]
Mesothelin 97% 98% [28]
Mesothelin & CA125 97% 98% [28]
sEGFRb 64% 65% [31]
sEGFR & CA125 68% 100% [32]
M-CSFb 70% 94% [35]
M-CSF & CA125 86% 86% [35]
sFRAb 59% 98% [36]
a

The sensitivity and specificity values are for differentiating benign disease for OvCa

b
  • sEGFR: soluble epidermal growth factor receptor;
  • M-CSF: macrophage colony stimulating factor;
  • s-FRA: soluble folate receptor alpha